MedTwenty Indices and trackers are editorial indicators and business information. They are not investment, financial, legal or medical advice, and not a regulated benchmark.
Summary
Minimal-residual-disease and tumour-informed sequencing company, being acquired by Tempus in a $1.5bn transaction.
Finances
Not published (small company accounts)
Timeline
No verified timeline entries yet.